Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Leukemia
Myelodysplastic Syndromes
Lymphoma
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-01-27

Last Posted Date: 2019-09-17

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT00044954

Locations: 🇺🇸
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, United States

and more 11 locations

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Not Applicable

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Myelodysplastic Syndromes
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission
Acute Undifferentiated Leukemia

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 160

Registration Number: NCT00014235

Locations: 🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

and more 8 locations

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

Phase 2

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Childhood Acute Lymphoblastic Leukemia in Remission
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia

Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Biological: donor lymphocytes
Drug: cyclosporine
Radiation: total-body irradiation
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2012-12-07

Lead Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Target Recruit Count: 30

Registration Number: NCT00031655

Locations: 🇺🇸
Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Oregon Health and Sciences University, Portland, Oregon, United States

Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-08

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 7

Registration Number: NCT00020800

Locations: 🇸🇪
Huddinge University Hospital, Stockholm, Sweden
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Barrett Cancer Center, Cincinnati, Ohio, United States

and more 15 locations

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: alemtuzumab
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: melphalan
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 51

Registration Number: NCT00027560

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Genta Incorporated

Registration Number: NCT00024440

Locations: 🇺🇸
Genta Incorporated, Berkeley Heights, New Jersey, United States

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

Phase 1

Completed

Conditions: Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Biological: therapeutic allogeneic lymphocytes
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00005851

Locations: 🇺🇸
Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 3 locations

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Phase 2

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 52

Registration Number: NCT00008307

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Phase 2

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Nonmalignant Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: anti-thymocyte globulin
Drug: busulfan
Drug: fludarabine phosphate
Drug: carboplatin
Radiation: total-body irradiation
Drug: cyclophosphamide
Drug: melphalan
Drug: etoposide
Drug: thiotepa

First Posted Date: 2003-01-27

Last Posted Date: 2021-08-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 361

Registration Number: NCT00003816

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission
Childhood Myelodysplastic Syndrome
Childhood Renal Cell Carcinoma
Chronic Myelomonocytic Leukemia
Clear Cell Renal Cell Carcinoma
de Novo Myelodysplastic Syndrome
Metastatic Renal Cell Cancer
Previously Treated Myelodysplastic Syndrome

Interventions: Drug: Fludarabine Phosphate
Radiation: Total-Body Irradiation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Mycophenolate Mofetil

First Posted Date: 2003-01-27

Last Posted Date: 2019-12-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 106

Registration Number: NCT00027820

Locations: 🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States
🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy